Hard to Treat Diseases (HTDS): Novartis to buy majority in China's Tian...

Reply Private New

Replies (1) Next 10 Prev Next

Send PM Follow Ignore

Followers	113
Posts	25553
Boards Moderated	4
Alias Born	02/01/2004

Ubertino

Re: None

Monday, 11/09/2009 5:21:30 PM

Monday, November 09, 2009 5:21:30 PM

Novartis to buy majority in China's Tianyuan $125M

Associated Press, 11.04.09, 02:13 AM EST

BASEL, Switzerland -- Pharmaceuticals company Novartis AG said Wednesday it is paying $125 million for an 85 percent stake in Chinese vaccine maker Zhejiang Tianyuan Bio-Pharmaceutical Co. Ltd.

Privately-held Tianyuan sells vaccines against diseases such as hemorrhagic fever with renal syndrome, or HFRS, caused by hantaviruses, and conducts research into "various preventable viral and bacterial diseases," Novartis said.

The Chinese company had net sales of $25 million in 2008.

The deal, which requires regulatory approval, comes a day after Novartis announced it will invest some $1.25 billion in its research centers in China over the next five years.

Copyright 2009 Associated Press. All rights reserved. This material may not be published broadcast, rewritten, or redistributed

http://www.forbes.com/feeds/ap/2009/11/04/business-eu-switzerland-novartis-china_7082666.html